Merck Investigator Studies Program (MISP): Fertility

September 29, 2022

The following areas are of interest to Investigator Studies Program Committee:  

  • Studies investigating modifications of corifollitropin alfa (CFA) stimulation protocols to the freeze-all setting aimed at optimizing ART cycle outcomes, time to pregnancy, flexibility and cost-efficiency.
  • Studies investigating optimizing CFA use in patients with a predicted poor oocyte yield response.
  • Studies that use innovative technology and algorithms to enhance embryo selection with CFA vs. conventional gonadotropins.
  • Studies that evaluate further optimization of the post-CFA follicular stimulating hormone (rFSH) regimen and determine the parameters to support optimization (e.g. # follicles, age, endocrine environment)
  • Studies evaluating Progestin Primed Ovarian Stimulation (PPOS) in CFA versus recombinant (r)FSH cycles for ovarian response and donor compliance
  • Evaluate the effect of modifications of ovarian stimulation on late follicular progesterone rise (eg. CFA, recombinant Luteinizing Hormone, human Menopausal Gonadotropin

Deadline: Rolling deadline

Dollar Amount: Varies

Eligibility: Investigators at all career levels are eligible to apply

Full RFP: